Acute side effects of adjuvant chemotherapy for early-stage breast cancer
- Charles L Shapiro, MD
Charles L Shapiro, MD
- Professor of Medicine
- Co-Director of Dubin Breast Center
- Director of Translational Breast Cancer Research
- Director of Cancer Survivorship, Tisch Cancer Institute
Adjuvant chemotherapy results in an improvement in both disease-free and overall survival and is routinely administered for women with early-stage breast cancer. However, treatment is associated with both acute and long-term complications for the breast cancer survivor. The number, nature, and costs of severe adverse effects experienced by women receiving adjuvant chemotherapy for breast cancer are relatively unknown, but may be more common than suspected from what has been reported from clinical trials.
This was illustrated in a series of 12,239 women aged 63 or younger with newly diagnosed breast cancer between 1998 and 2002, 4075 of whom were treated with adjuvant chemotherapy . Women who were treated with chemotherapy were significantly more likely to visit emergency rooms for all causes (61 versus 42 percent) and for serious adverse effects (16 versus 5 percent). For patients receiving chemotherapy, the major reasons prompting hospitalization or an emergency room visit during the year after their breast cancer diagnosis were:
●Fever or infection
●Neutropenia or thrombocytopenia
●Dehydration or electrolyte disorders
- Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006; 98:1108.
- Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344:1997.
- Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.
- Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 2011; 29:1472.
- Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.
- Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381.
- Akerley W 3rd. Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest 2000; 117:152S.
- Garrison JA, McCune JS, Livingston RB, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park) 2003; 17:271.
- NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors, Version 1.2012 http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf (Accessed on May 21, 2012).
- Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33:3199.
- Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.
- Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358:2482.
- Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev 2011; 12:282.
- Gadéa E, Thivat E, Planchat E, et al. Importance of metabolic changes induced by chemotherapy on prognosis of early-stage breast cancer patients: a review of potential mechanisms. Obes Rev 2012; 13:368.
- Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. Acta Oncol 2011; 50:167.
- Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012; 62:243.
- Sadler IJ, Jacobsen PB. Progress in understanding fatigue associated with breast cancer treatment. Cancer Invest 2001; 19:723.
- Berger AM. Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncol Nurs Forum 1998; 25:51.
- Fan HG, Houédé-Tchen N, Yi QL, et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005; 23:8025.
- Broeckel JA, Jacobsen PB, Horton J, et al. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998; 16:1689.
- Bower JE, Ganz PA, Desmond KA, et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18:743.
- North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17:242.
- Duijts SF, van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012; 30:4124.
- Dodin S, Blanchet C, Marc I, et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst Rev 2013; :CD007410.
- Walshe JM, Denduluri N, Swain SM. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J Clin Oncol 2006; 24:5769.
- Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24:1045.
- Schmid P, Untch M, Kossé V, et al. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol 2007; 25:2509.
- Bernard-Marty C, Mano M, Paesmans M, et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann Oncol 2003; 14:693.
- Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986; :105.
- Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29:1110.
- Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5. J Clin Oncol 2005; 23:6002.
- Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302.
- Swain SM, Land SR, Ritter MW, et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009; 113:315.
- Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007; 30:126.
- Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116:791.
- Davis AL, Klitus M, Mintzer DM. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: the effect of the addition of taxanes. Clin Breast Cancer 2005; 6:421.
- Fornier MN, Modi S, Panageas KS, et al. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104:1575.
- Berliere M, Dalenc F, Malingret N, et al. Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel. BMC Cancer 2008; 8:56.
- Hulvat MC, Jeruss JS. Fertility preservation options for young women with breast cancer. Curr Opin Obstet Gynecol 2011; 23:174.
- Venturini M, Del Mastro L, Aitini E, et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005; 97:1724.
- Stearns V, Schneider B, Henry NL, et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006; 6:886.
- Takada K, Arefayene M, Desta Z, et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202.
- Schover LR. Premature ovarian failure and its consequences: vasomotor symptoms, sexuality, and fertility. J Clin Oncol 2008; 26:753.
- Bordeleau L, Pritchard K, Goodwin P, Loprinzi C. Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther 2007; 29:230.
- Su HI. Measuring ovarian function in young cancer survivors. Minerva Endocrinol 2010; 35:259.
- Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010; 116:592.
- SPECIFIC ISSUES RELATED TO INDIVIDUAL AGENTS
- - Neurotoxicity
- - Pulmonary toxicity
- - Hepatotoxicity
- - Musculoskeletal side effects
- GENERAL ISSUES RELATED TO CHEMOTHERAPY
- - Neutropenia
- - Anemia
- Gastrointestinal side effects
- - Nausea and vomiting
- - Mucositis
- - Weight gain
- Dermatologic toxicity
- - Cutaneous side effects
- - Alopecia
- Sexual and reproductive side effects
- - Vasomotor symptoms
- - Chemotherapy-induced amenorrhea
- Risk factors
- Menopausal symptoms
- INFORMATION FOR PATIENTS